SecBot SecBot
424B5 ·Filed Apr 15, 2026

BEATW

HeartBeam, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago SEC0001213900-26-044264
Notable filing: 424B5
Actionable Insight ▼ Bearish

Traders should be cautious of the significant dilution and the company's going concern uncertainty. While the capital will support commercialization and R&D initiatives, the stock may face downward pressure due to the share increase and financial instability. Monitor how effectively management deploys the capital toward commercialization milestones.

DirectionBearish
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
BEATW ▼ -85.49% at T+60d
SHORT call ✓ call won +85.49% · α vs SPY +92.54% · entry $0.1351 → $0.0196
Entry = T+0 close
Apr 15, 2026
via day close
T+1d
0.00%
call 0.00% · α +1.21%
$0.1351
settled 7mo ago
T+5d
0.00%
call 0.00% · α +0.98%
$0.1351
settled 6mo ago
T+20d
0.00%
call 0.00% · α +5.82%
$0.1351
settled 6mo ago
T+60d
-85.49%
call +85.49% · α +92.54%
$0.0196
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

HeartBeam, Inc. (BEATW) is raising approximately $8.9 million through a public offering of 12.5 million shares at $0.80 per share, despite expressing substantial doubt about its ability to continue as a going concern. The company plans to use the proceeds for commercialization, R&D, and working capital, but existing shareholders face immediate and substantial dilution.

Key Facts

  • Company raising $8.9 million through issuance of 12.5 million shares at $0.80 per share
  • Management and auditors have expressed substantial doubt about the company's ability to continue as a going concern
  • Net tangible book value per share will increase from $0.06 to $0.22 after the offering, creating $0.58 per share dilution for new investors
  • Proceeds will be used for commercialization of FDA-cleared ECG system, development of extended-wear patch, heart attack detection initiatives, and general corporate purposes
  • The offering includes underwriter warrants to purchase up to 625,000 additional shares at $0.92 per share

Financial Impact

Raises $8.9 million in net proceeds, increasing shares outstanding from 41.1 million to 53.6 million (55.5 million if over-allotment is exercised)

cashdilutionworking capital

Risk Factors

  • Substantial doubt about the company's ability to continue as a going concern
  • Significant dilution for new investors ($0.58 per share)
  • No guarantee that the raised capital will be used effectively or generate returns

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001213900-26-044264
Document: 0001213900-26-044264-index-headers.html0001213900-26-044264
Document: 0001213900-26-044264-index.html0001213900-26-044264
Document: 0001213900-26-044264.txt0001213900-26-044264

US Market Status

Market Closed — Opens in 8h 22m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 16, 2026